Across TCGA pan-cancer cohorts, CRYM-AS1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CRYM-AS1 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CRYM-AS1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRYM-AS1 expression acts as an unfavorable survival marker.

BLCA and PRAD are the cancer types where CRYM-AS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.078	0.594	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CRYM-AS1 tumor-vs-normal RNA expression · all CRYM-AS1 data types